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unanswered question1. Facts and figures
Breast cancer has now overtaken lung cancer as the world's
mostly commonly-diagnosed cancer, according to statistics
released by the International Agency for Research on Cancer
(IARC) in December 2020. Five to eight percent of newly diagnosed
breast cancer cases are metastatic at diagnosis. Intriguingly this
number has not changed over the last decade even with the wide-
spread use of more sensitive systemic staging modalities like PET-
CT.
Since the first patient was recruited in the Tata memorial trial in
2005 [1] we have seen significant advances in the field of targeted
therapies for ERþ and Her-2 positive breast cancer and immuno-
therapy for triple negative breast cancer (TNBC) leading to
improvement in the control of systemic disease. Survival for these
patients especially in ER and HER2 positive patients raised to
20e40% at 5 years thus making the topic of locoregional therapy
(LRT) of the primary tumour increasingly relevant.
2. The available retrospective data
The majority of available data come from retrospective trials
analysing studies conducted before the new millennium. The con-
clusions of all the published meta-analyses including large popula-
tion based studies and smaller institutional studies point to an
overall survival (OS) benefit from primary tumour resection in de
novo metastatic breast cancer.
We should not forget however that in many of these studies the
recruitment interval was as large as 20 years with the consequent
heterogeneity in inclusion criteria and available treatments.
In these studies women offered primary tumour resection were
predominantly younger, fitter and with less metastatic burden thus
introducing the risk of selection bias.
3. The randomized clinical trials (RCTs) data
At the present moment four prospective randomized studies
have completed accrual and presented their results [1e4]. Three
of these trials have been published in peer-reviewed journals and
one trial (the ECOG-ACRIN) presented its preliminary findings at
the ASCO 2020 virtual meeting. The first trial, The Tata MemorialDOI of original article: https://doi.org/10.1016/j.breast.2021.05.003.
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mary systemic treatment, showed no OS benefit from LRT and was
heavily criticized for suboptimal systemic therapy with a limited
use of taxanes and omission of anti-HER2 therapy in 92% of patients
with HER2 positive disease [1]. The subsequent Turkish study, ran-
domized patients at presentation between surgery of the primary
versus no surgery, initially reported no difference in survival at 3
years of follow up, however, with a longer follow-up of 5 years,
the median survival was significantly improved for patients
receiving local therapy. However in this trial there was an imbal-
ance between the arms with the group proposed for surgery having
younger patients, more frequently ER positive and HER2 negative,
and with single bone metastases, factors that could have had
impact on the result [2]. Moreover the patients in the treatment
arm were offered upfront surgery. The Austrian POSYTIVE trial
due to poor recruitment, was stopped prematurely after 5 years
when only 90 patients of the pre-planned 254, had been enrolled,
45 in each arm and therefore it did not achieve the required statis-
tical power for a reliable analysis [3]. Nevertheless the two groups
were balanced and again no advantage for surgery of the primary
tumour was observed. The preliminary data of the fourth trial pre-
sented at ASCO 2020 demonstrated again no significant difference
in OS but reported that the 3-year locoregional recurrence or pro-
gression was significantly higher in the systemic therapy alone
arm [4]. We eagerly await the full peer-reviewed publication and
longer follow up data for this trial.
4. Where do we go from here?
In this meta-analysis of 4 RCTs spanning 970 patients, Reinhorm
et al. [5] reports that LRT for the primary tumour confers no OS
benefit in patients presenting with de novo stage IV breast cancer
despite the significant improvement in locoregional control. In
contrast with previousmeta-analyses [6] the authors have included
only RCTs in order to overcome the selection bias introduced in
retrospective studies.
Due to the important heterogeneity of the reported studies, it is
difficult to accept the conclusionwithout uncertainties. However in
the pooled analysis compared to the control group, surgery of the
primary was not associated with OS in the ITT population. Multiple
sensitivity analysis for OS and leave-one-out sensitivity analysis forC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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was not associated with an OS improvement in any tumour subtype
or bone only versus visceral disease.
De novo stage IV breast cancer displays extensive heterogeneity
in relation to its metastatic pattern and differential response of the
primary tumour and metastatic sites to systemic therapy. In the
absence of well-designed, adequately powered, and carefully con-
ducted RCTs utilizingmodern targeted biological agents and immu-
notherapy, the local management strategy of the primary tumour of
every patient with de novo stage IV breast cancer should be deter-
mined only after a careful multidisciplinary discussion [7].
Excellent responders to systemic therapy at both the primary
and distant disease sites are unlikely to derive a survival benefit
from local surgery and this was observed in the prospective registry
study TBCRC 013 [8]. However patients whose primary tumour
does not respond well to systemic therapy, but with an important
response of the metastatic sites, will derive benefit from local sur-
gery in terms not only of optimal local control but also by reducing
the burden of therapy resistant residual tumour cells although OS
benefit is not proven. The benefit of local therapy in optimising
local disease control has been observed in this meta-analysis and
in the individual studies included [5]. Furthermore, patients with
ER þ oligometastatic disease confined to bone are most likely to
benefit from LRT of the primary tumour in view of their prolonged
survival as shown by the recent results of the BOMET protocol
MF14-01 partially presented this year in St Gallen, although again
an imbalance between the groups (bone only vs multiple bone me-
tastases) was observed [9].
We eagerly await the results of NRG BR002 to further clarify the
role of ablative therapy to all sites of disease in patients with oligo-
metastatic disease [10].
All the randomized trials designed to evaluate the impact of sur-
gery of the primary tumour in de novo metastatic breast cancer
have reported some data with the exception of the Japanese trial
PRIM-BC, with results expected before 2024 [11].
Taking into consideration all the information already available if
primary tumour ablation is considered in de novo metastatic breast
cancer, the local surgical approach for treating the intact primary
tumour should be preferably conservative, when feasible, aiming
to remove the tumour with clear resection margins. In the absence
of a conclusively proven OS benefit, more radical surgical ap-
proaches such as mastectomy should be discouraged. Although
the role of radiotherapy after surgery of the primary has not been
systematically evaluated in the analysed randomized trials, meta-
analysis of existent retrospective studies suggested that, in addition
to local surgery, radiation therapy further improves local control
and may elicit a systemic immune response against the tumour
and therefore it should be considered an integral part of LRT [6].1715. Conclusion
The progress in addressing this unresolved issue has been slow.
We are all aware of the difficulty in conducting these trials and the
heterogeneity inherent to the definition of de novo metastatic
breast cancer (Table 1). We anticipate that with the results yet to
be published, a pooled analysis of patient data, from all the ran-
domized trials will help us to obtain a more definite response to
our still unanswered question.
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